Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Friday, 09 / 25 / 2020

Articles

Abstract

REVIEW ARTICLE

Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?

Yue Chang1,, and  Hai Li*,1,2

1  Division of Gastroenterology and Hepatology, Tianjin Xiqing Hospital, Tianjin, China
2  Tianjin Key Laboratory of Hepatopancreatic Fibrosis and Molecular Diagnosis and Treatment, Tianjin, China
*Correspondence to: Hai Li, Division of Gastroenterology and Hepatology, Tianjin Xiqing Hospital, No. 403 Xiqing Road, Xiqing District, Tianjin 300380, China. Tel: +86-22- 60578765, Fax: +86-22-24370605, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2020;8(2):222-229 DOI: 10.14218/JCTH.2020.00026
Received:April 6, 2020 Accepted: June 1, 2020 Published online: June 18, 2020

Abstract

The incidence rate and mortality of liver fibrosis caused by various etiologies are high throughout the world. Liver fibrosis, the subsequent cirrhosis and other serious related complications threaten the health of patients and represent a serious medical burden; yet, there is still a lack of approved methods to prevent or reverse liver fibrosis. Therefore, effective hepatic antifibrotic drugs are urgently needed. The activation and proliferation of hepatic stellate cells are still the mechanisms of fibrosis that remain the focus of therapeutic research. In recent years, significant progress has been made in the development and applicability of antifibrosis drugs. In this review, we summarize the effectiveness and safety of available antifibrosis drugs utilizing different targets. In addition, some characteristics of antifibrosis drugs in phase II and III trials are introduced in detail.

Keywords

Antifibrotic agents, Fibrosis, Liver, Reversal, Pharmacotherapy

Journal of Clinical and Translational Hepatology 2020 vol. 8, 222-229  [ Html  ] [ PDF Full-text ]

© The Authors 2018. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 

 logo

You are here: Home